Once weekly subcutaneous injection of TransCon hGH + Once daily subcutaneous injection of Genotropin
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency, Pediatric
Conditions
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Trial Timeline
Dec 13, 2016 → Jan 17, 2019
NCT ID
NCT02781727About Once weekly subcutaneous injection of TransCon hGH + Once daily subcutaneous injection of Genotropin
Once weekly subcutaneous injection of TransCon hGH + Once daily subcutaneous injection of Genotropin is a phase 3 stage product being developed by Ascendis Pharma for Growth Hormone Deficiency, Pediatric. The current trial status is completed. This product is registered under clinical trial identifier NCT02781727. Target conditions include Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02781727 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency, Pediatric